Clinical significance of BIM deletion polymorphism on chemoradiotherapy in patients with non-small cell lung cancer.

1. [1]Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer

J Clin. 2019; 69: 7-34.

2. Chen VW, Ruiz BA, Hsieh MC, Wu XC, Ries LA, Lewis DR. Analysis

of stage and clinical/prognostic factors for lung cancer from SEER

registries: AJCC staging and collaborative stage data collection system. Cancer. 2014;120(Suppl 23):3781-3792.

3. NCCN.org. Non-Small Cell Lung Cancer. NCCN Clinical Practice

Guidelines in Oncology (NCCN Guidelines®) 2020; Version 6.2020.

https://www.nccn.org/profe​s sion​a ls/physi​c ian_gls/pdf/nscl.pdf.

Accessed June, 26 2020

4. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med.

2017;377:1919-1929.

5. Galluzzi L, Vitale I, Warren S, et al. Consensus guidelines for the

definition, detection and interpretation of immunogenic cell death.

J Immunother Cancer. 2020;8:e000337.

6. Meng X, Feng R, Yang L, Xing L, Yu J. The role of radiation oncology

in immuno-oncology. Oncologist. 2019;24:S42-s52.

7. Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer. 2003;3:117-129.

8. Huang L, Snyder AR, Morgan WF. Radiation-induced genomic instability and its implications for radiation carcinogenesis. Oncogene.

2003;22:5848-5854.

9. Sunters A, Fernández de Mattos S, Stahl M, et al. FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated

breast cancer cell lines. J Biolog Chem. 2003;278:49795-49805.

10. Li R, Moudgil T, Ross HJ, Hu HM. Apoptosis of non-small-cell lung

cancer cell lines after paclitaxel treatment involves the BH3-only

proapoptotic protein Bim. Cell Death Differ. 2005;12:292-303.

11. Tan TT, Degenhardt K, Nelson DA, et al. Key roles of BIM-driven

apoptosis in epithelial tumors and rational chemotherapy. Cancer

Cell. 2005;7:227-238.

12. Klotz DM, Nelson SA, Kroboth K, et al. The microtubule poison

vinorelbine kills cells independently of mitotic arrest and targets

cells lacking the APC tumour suppressor more effectively. J Cell Sci.

2012;125:887-895.

13. Miller AV, Hicks MA, Nakajima W, Richardson AC, Windle JJ, Harada

H. Paclitaxel-induced apoptosis is BAK-dependent, but BAX and

BIM-independent in breast tumor. PLoS One. 2013;8:e60685.

14. Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and

disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell

Biol. 2019;20:175-193.

15. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities

that mediate cell death. Nat Rev Mol Cell Biol. 2008;9:47-59.

16. Ng KP, Hillmer AM, Chuah CT, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to

tyrosine kinase inhibitors in cancer. Nat Med. 2012;18:521-528.

17. Costa DB, Halmos B, Kumar A, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR

mutations. PLoS Medicine. 2007;4:1669-1679. discussion 1680.

18. Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A.

Gefitinib-induced killing of NSCLC cell lines expressing mutant

EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS

Medicine. 2007;4:1681-1689. discussion 1690.

19. Gong Y, Somwar R, Politi K, et al. Induction of BIM is essential for

apoptosis triggered by EGFR kinase inhibitors in mutant EGFRdependent lung adenocarcinomas. PLoS Medicine. 2007;4:e294.

20. Soh SX, Siddiqui FJ, Allen JC, et al. A systematic review and

meta-analysis of individual patient data on the impact of the

BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. Oncotarget.

2017;8:41474-41486.

21. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer

Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification

of malignant tumours. J Thorac Oncol. 2007;2:706-714.

22. Tanimoto A, Takeuchi S, Arai S, et al. Histone deacetylase 3 inhibition overcomes BIM deletion polymorphism-mediated osimertinib resistance in EGFR-mutant lung cancer. Clin Cancer Res.

2017;23:3139-3149.

11

WAKABAYASHI et al.

23. Kawada K, Yonei T, Ueoka H, et al. Comparison of chemosensitivity tests: clonogenic assay versus MTT assay. Acta Med Okayama.

2002;56:129-134.

24. Savry A, Carre M, Berges R, et al. Bcl-2-enhanced efficacy of microtubule-targeting chemotherapy through Bim overexpression: implications for cancer treatment. Neoplasia (New York, NY). 2013;15:49-60.

25. Yanagihara N, Kobayashi D, Kuribayashi K, Tanaka M, Hasegawa

T, Watanabe N. Significance of SALL4 as a drug-resistant factor in

lung cancer. Int J Oncol. 2015;46:1527-1534.

26. Izumi Y, Nakashima T, Masuda T, et al. Suplatast tosilate reduces

radiation-induced lung injury in mice through suppression of oxidative stress. Free Rad Biol Med. 2019;136:52-59.

27. O'Connor L, Strasser A, O'Reilly LA, et al. Bim: a novel member of the

Bcl-2 family that promotes apoptosis. EMBO J. 1998;17:384-395.

28. Yang JY, Xia W, Hu MC. Ionizing radiation activates expression of

FOXO3a, Fas ligand, and Bim, and induces cell apoptosis. Int J Oncol.

2006;29:643-648.

29. Nakagawa T, Takeuchi S, Yamada T, et al. EGFR-TKI resistance due

to BIM polymorphism can be circumvented in combination with

HDAC inhibition. Cancer Res. 2013;73:2428-2434.

3 0. Li Z, Zhang J, Liu Z, Woo CW, Thiele CJ. Downregulation of Bim

by brain-derived neurotrophic factor activation of TrkB protects

neuroblastoma cells from paclitaxel but not etoposide or cisplatin-induced cell death. Cell Death Differ. 2007;14:318-326.

31. Czernick M, Rieger A, Goping IS. Bim is reversibly phosphorylated

but plays a limited role in paclitaxel cytotoxicity of breast cancer

cell lines. Biochem Biophys Res Commun. 2009;379:145-150.

32. Dronca RS, Liu X, Harrington SM, et al. T cell Bim levels reflect responses to anti-PD-1 cancer therapy. JCI Insight. 2016;1:e86014.

S U P P O R T I N G I N FO R M AT I O N

Additional supporting information may be found online in the

Supporting Information section.

How to cite this article: Wakabayashi Y, Masuda T, Fujitaka

K, et al. Clinical significance of BIM deletion polymorphism in

chemoradiotherapy for non-small cell lung cancer. Cancer Sci.

2020;00:1–11. https://doi.org/10.1111/cas.14711

...